Celltrion's Truxima leads US prescription market in February

An exterior view of Celltrion’s second factory in Incheon / Courtesy of Celltrion

Celltrion, a leading Korean biopharmaceutical company, said Tuesday its biosimilar Truxima, used to treat blood cancers, claimed the largest share of prescriptions in the United States in February.

Truxima accounted for 35.8 percent of U.S. prescriptions in its category during the month, the company said in a press release, marking the first time a biosimilar developed by a Korean firm has led the U.S. market.

Celltrion said growing demand in the U.S., the world's biggest pharmaceutical market, for its biosimilar products will help it achieve its earnings targets for the year.

It aims to post an operating profit of 1.7 trillion won ($1.1 billion) on sales of 5.3 trillion won in 2026, up from 1.16 trillion won and 4.16 trillion won, respectively, last year.

Celltrion plans to increase the share of new biosimilars in total sales to 70 percent this year, up from 54 percent in 2025.

The company has been expanding its global biosimilar portfolio, with the number of approved products rising to 11 from six. It aims to launch 18 biosimilars by 2030 and 41 by 2038.

Its only original drug, Zymfentra, is currently sold in the U.S. for autoimmune diseases and marketed as Remsima SC in Europe and other regions.